View of Incidence of Cardiotoxicity Associated with The Use of Pegylated Liposomal Doxorubicin in Gynecologic Malignancies

Return to Article Details Incidence of Cardiotoxicity Associated with The Use of Pegylated Liposomal Doxorubicin in Gynecologic Malignancies Download Download PDF